Roth Capital Reiterates Buy Following Conatus Pharmaceuticals (CNAT) Phase II Emricasan Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
Go back to Roth Capital Reiterates Buy Following Conatus Pharmaceuticals (CNAT) Phase II Emricasan Data
January 5, 2016 6:12 PM EST
Conatus Pharmaceuticals (NASDAQ: CNAT) 15% HIGHER; three-month, double-blind, placebo-controlled stage of the companys multicenter Phase 2 Liver Cirrhosis clinical trial showed a statistically significant reduction in caspase-cleaved cytokeratin 18 (cCK18) vs. placebo (p=0.04) in the overall patient population when adjusted for differences between treatment and placebo groups in baseline Model for End-stage Liver Disease (MELD)1 score and disease etiology as specified in the trial statistical analysis plan.
Epizyme, Inc. (NASDAQ: EPZM) 10% LOWER; announced that it intends to... More
January 5, 2016 4:38 PM EST
Conatus Pharmaceuticals (NASDAQ: CNAT) resumed trading and is up 9.8% after announcing that the three-month, double-blind, placebo-controlled stage... More
January 5, 2016 4:11 PM EST
Conatus Pharmaceuticals (NASDAQ: CNAT) to Resume Trading at 4.35 PM ET
...
More
January 5, 2016 4:07 PM EST
Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced that the three-month, double-blind, placebo-controlled stage of the companys multicenter Phase 2 Liver Cirrhosis clinical trial showed a statistically significant reduction in caspase-cleaved cytokeratin 18 (cCK18) vs. placebo (p=0.04) in the overall patient population when adjusted for differences... More
January 5, 2016 4:01 PM EST
Conatus Pharmaceuticals (NASDAQ: CNAT) halted, news pending
...
More
